The adoptive transfer of sensitized T lymphocytes has been shown to effectively mediate the regression of established tumors. Using the weakly immunogenic MCA 105 sarcoma, we have developed an in vitro sensitization (IVS) procedure which allowed cellular expansion as well as augmentation of the therapeutic efficacy of immune spleen cells. With the IVS procedure, we were able to generate, from tumor-bearing mice, lymphocytes with therapeutic efficacy against established pulmonary metastases. Before culture these lymphoid cells did not exhibit antitumor reactivity. Since effective T lymphocytes could not be generated from normal mice, it became evident that progressive growth of the MCA 105 tumor elicited pre-effector cells from which antitumor effector cells could be induced by IVS. We have recently extended these observations to two nonimmunogenic murine sarcomas. The MCA 101 and MCA 102 tumors failed to elicit a systemic immunty in syngeneic hosts by a variety of immunization protocols including tumor growth and excision, immunization with irradiated tumor cells as well as with mixtures of various doses of tumor cells and a bacterial adjuvant, Corynebacterium parvum. However, preliminary experimental results demonstrated that immunization with tumor cells and adjuvant elicted pre-effector cells in the draining lymph node. IVS of these lymphoid cells resulted in the generation of effector cells capable of mediating the regression of established MCA 101 and MCA 102 tumors. The purpose of the proposed studies is to analyze further the optimal conditions and cellular mechanisms involved in eliciting therapeutic pre-effector cells in vivo and effector cells invitro which have therapeutic activity against these """"""""nonimmmunogenic tumors."""""""" The studies in this proposal seek to: 1) determine the immunization conditions necessary for eliciting pre-effector cells. 2) elucidate mechanisms of cellular interactions leading to the sensitization of pre-effector cells: 3) elucidate conditions of IVS for induction of therapeutic lymphocytes and to determine criteria for cellular expansion in culture: 4) determine the immunologic specificity of adoptive immunotherapy; 5) determine the effect of exogenous IL-2 on the function, distribution and proliferation of transferred IVS effector cells in vivo: and, 6) determine the therapeutic efficacy of IVS cells in the treatment of advanced metastases in various organs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA049231-02
Application #
3193252
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1988-06-01
Project End
1993-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Shu, S; Krinock, R A; Matsumura, T et al. (1994) Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277-88
Shu, S; Sussman, J J; Chang, A E (1993) In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents. J Immunother Emphasis Tumor Immunol 14:279-85
Yoshizawa, H; Chang, A E; Shu, S Y (1992) Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res 52:1129-36
Yoshizawa, H; Sakai, K; Chang, A E et al. (1991) Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 134:473-9
Yoshizawa, H; Chang, A E; Shu, S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-37
Sakai, K; Chang, A E; Shu, S Y (1990) Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Cancer Res 50:4371-6
Sakai, K; Chang, A E; Shu, S (1990) Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell Immunol 129:241-55
Shu, S Y; Chou, T; Sakai, K (1989) Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143:740-8
Ward, B A; Shu, S; Chou, T et al. (1988) Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J Immunol 141:1047-53
Chou, T; Bertera, S; Chang, A E et al. (1988) Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol 141:1775-81